全院实施皮下胰岛素方案治疗糖尿病酮症酸中毒的结局评估
该研究为回顾性评估前瞻性实施的皮下胰岛素方案,纳入2010年1月1日至2019年12月31日21家医院7989例糖尿病酮症酸中毒住院患者,干预点自2017年起使用皮下胰岛素方案,与20家标准治疗医院行双重差分比较。实施后干预点80.3%住院首先接受皮下胰岛素(对照点12.8%)。干预点ICU入住调整率比0.43(95%CI 0.33-0.56),较对照点降低57%;30天再入院调整率比0.50(95%CI 0.25-0.99),降低50%;住院时长与死亡率无显著变化。作者认为该方案与ICU需求及再入院显著下降相关,无不良事件增加的证据。
要点
- 实施后干预点80.3%住院首先接受皮下胰岛素,对照点仅12.8%;实施前分别为13.4%与14.7%。
- 干预点ICU入住调整率比0.43(95%CI 0.33-0.56),较对照点降低57%。
- 干预点30天再入院调整率比0.50(95%CI 0.25-0.99),较对照点降低50%。
- 住院时长与死亡率无显著变化。
- 作者认为皮下胰岛素方案与ICU需求及再入院显著下降相关,无不良事件增加的证据。
适用人群与场景
- 2010年1月1日至2019年12月31日在21家医院住院的糖尿病酮症酸中毒患者;实施前阶段为2010至2015年,实施后阶段为2017至2019年。
- 干预点为1家自2017年起使用皮下胰岛素方案的医院,对照为20家使用标准治疗的医院。
处置流程与药物剂量
- 干预点自2017年起实施皮下胰岛素治疗糖尿病酮症酸中毒方案;实施前皮下胰岛素作为首个胰岛素使用者为干预点40例(13.4%)、对照点651例(14.7%),实施后干预点98例(80.3%)、对照点402例(12.8%)。
研究设计与关键结果
- 共7989例糖尿病酮症酸中毒住院,实施前4739例(59.3%),实施后3250例(40.7%);总体平均(SD)年龄42.3(17.7)岁,女性4137例(51.8%)。
- 干预点ICU入住调整率比0.43(95%CI 0.33-0.56),较对照点降低57%。
- 干预点30天再入院调整率比0.50(95%CI 0.25-0.99),较对照点降低50%。
- 住院时长与死亡率无显著变化。
证据类型、等级与局限
- 研究类型:队列研究,为对前瞻性实施的皮下胰岛素方案的回顾性评估;数据来自2010年1月1日至2019年12月31日21家医院,数据分析于2020年10月至2022年1月进行。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于皮下胰岛素的糖尿病酮症酸中毒治疗方案与ICU需求及再入院显著下降相关,且无不良事件增加的证据。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Standard diabetic ketoacidosis care in the US includes intravenous insulin treatment in the intensive care unit. Subcutaneous (SQ) insulin could decrease intensive care unit need, but the data are limited.
OBJECTIVE: To assess outcomes after implementation of an SQ insulin protocol for treating diabetic ketoacidosis.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study is a retrospective evaluation of a prospectively implemented SQ insulin protocol. The study was conducted at an integrated health care system in Northern California. Participants included hospitalized patients with diabetic ketoacidosis at 21 hospitals between January 1, 2010, and December 31, 2019. The preimplementation phase was 2010 to 2015, and the postimplementation phase was 2017 to 2019. Data analysis was performed from October 2020 to January 2022.
EXPOSURE: An SQ insulin treatment protocol for diabetic ketoacidosis.
MAIN OUTCOMES AND MEASURES: Difference-in-differences evaluation of the need for intensive care, mortality, readmission, and length of stay at a single intervention site using an SQ insulin protocol from 2017 onward compared with 20 control hospitals using standard care.
RESULTS: A total of 7989 hospitalizations for diabetic ketoacidosis occurred, with 4739 (59.3%) occurring before and 3250 (40.7%) occurring after implementation. The overall mean (SD) age was 42.3 (17.7) years, with 4137 hospitalizations (51.8%) occurring among female patients. Before implementation, SQ insulin was the first insulin used in 40 intervention (13.4%) and 651 control (14.7%) hospitalizations. After implementation, 98 hospitalizations (80.3%) received SQ insulin first at the intervention site compared with 402 hospitalizations (12.8%) at control sites. The adjusted rate ratio for intensive care unit admission was 0.43 (95% CI, 0.33-0.56) at the intervention sites, a 57% reduction compared with control sites, and was 0.50 (95% CI, 0.25-0.99) for 30-day hospital readmission, a 50% reduction. There were no significant changes in hospital length of stay and rates of death.
CONCLUSIONS AND RELEVANCE: These findings suggest that a protocol based on SQ insulin for diabetic ketoacidosis treatment was associated with significant decreases in intensive care unit need and readmission, with no evidence of increases in adverse events.
参考来源
- Rao P, Jiang SF, Kipnis P, et al. Evaluation of Outcomes Following Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic Ketoacidosis. JAMA Netw Open. 2022. PMID: 35389497. doi:10.1001/jamanetworkopen.2022.6417
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。